GT Biopharma Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) January 6, 2022
GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021 December 8, 2021
GT Biopharma Abstract on Novel B7-H3 Immune Checkpoint Targeting Broad Spectrum Solid and Hematologic Malignancies Accepted for Presentation at ESMO IO Congress 2021 November 30, 2021
GT BioPharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update November 10, 2021
GT Biopharma Announces Executive Leadership Transition to Implement Next Phase of Strategic Journey November 8, 2021
GT BioPharma's Next Generation Camelid TriKE® Nanobody Platform Highlighted at ESMO Congress 2021 September 20, 2021
GT Biopharma Announces Updated Positive Safety Data From Phase 1 GTB-3550 Monotherapy TriKE™ Trial an Investigational Immunotherapy for Refractory Cancers to be Presented at ESMO Congress 2021 September 15, 2021
GT Biopharma Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager -TriKE®, Into IND-Enabling Studies September 13, 2021
